Alnylam Pharmaceuticals (NASDAQ:ALNY) – Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy - Press Release
– Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyo
District Of Columbia United States United Kingdom Pushkal Garg Mathew Maurer International Symposium On Amyloidosis
Source: wiredprnews.com